Your browser doesn't support javascript.
Case Report: Precision COVID-19 Immunization Strategy to Overcome Individual Fragility: A Case of Generalized Lipodystrophy Type 4.
Zaffina, Salvatore; Piano Mortari, Eva; Di Prinzio, Reparata Rosa; Cappa, Marco; Novelli, Antonio; Agolini, Emanuele; Raponi, Massimiliano; Dallapiccola, Bruno; Locatelli, Franco; Perno, Carlo Federico; Carsetti, Rita.
  • Zaffina S; Occupational Medicine/Health Technology Assessment and Safety Research Unit, Clinical-Technological Innovations Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Piano Mortari E; Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Di Prinzio RR; Occupational Medicine/Health Technology Assessment and Safety Research Unit, Clinical-Technological Innovations Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Cappa M; Unit of Endocrinology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Novelli A; Laboratory of Medical Genetics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Agolini E; Laboratory of Medical Genetics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Raponi M; Medical Direction, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Dallapiccola B; Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Locatelli F; Department of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Perno CF; Sapienza, University of Rome, Rome, Italy.
  • Carsetti R; Microbiology and Diagnostic Immunology Unit and Multimodal Medicine Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Front Immunol ; 13: 869042, 2022.
Article in English | MEDLINE | ID: covidwho-1809405
ABSTRACT
A 48-year-old patient affected with congenital generalized lipodystrophy type 4 failed to respond to two doses of the BNT162b2 vaccine, consisting of lipid nanoparticle encapsulated mRNA. As the disease is caused by biallelic variants of CAVIN1, a molecule indispensable for lipid endocytosis and regulation, we complemented the vaccination cycle with a single dose of the Ad26.COV2 vaccine. Adenovirus-based vaccine entry is mediated by the interaction with adenovirus receptors and transport occurs in clathrin-coated pits. Ten days after Ad26.COV2 administration, S- and RBD-specific antibodies and high-affinity memory B cells increased significantly to values close to those observed in Health Care Worker controls.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Lipodystrophy, Congenital Generalized / Adenovirus Vaccines / COVID-19 Type of study: Case report / Observational study Topics: Vaccines / Variants Limits: Humans / Middle aged Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.869042

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Lipodystrophy, Congenital Generalized / Adenovirus Vaccines / COVID-19 Type of study: Case report / Observational study Topics: Vaccines / Variants Limits: Humans / Middle aged Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.869042